Loading your page…
Each register with its number of medicines and a few of them.
Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.
CBG-MEB · 5 medicines
FDA · 3 medicines
TFDA · 2 medicines
Anvisa · 1 medicine
EMA · 1 medicine
ALIMS · 1 medicine
HSA · 1 medicine
Every register, a page at a time. Strengths and packs are on each medicine’s page.
26 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Rybrevant | United States | 350MG/7ML | injectable | Marketed | Janssen Biotech |
| Rybrevant FasproCombination | United States | 10ML, 14ML | injection | Marketed | Janssen Biotech |
| Rybrevant FasproCombination | United States | 1,600MG/20,000 UNITS PER 10ML, 2,240MG/28,000 UNITS PER 14ML, 2,400MG/30,000 UNITS PER 15ML … | vial | Marketed | Janssen Biotech |
| Rybrevant | European Union | Authorised | Janssen-Cilag International N.V. | ||
| Rybrevant | Italy | Soluzione iniettabile | Authorised | Janssen-Cilag International N.V. | |
| Rybrevant 1600 MG Solucion Inyectable | Spain | 1600 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 2240 MG Solucion Inyectable | Spain | 2240 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 2400 MG Solucion Inyectable | Spain | 2400 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 3520 MG Solucion Inyectable | Spain | 3520 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 350 MG Concentrado Para Solucion Para Perfusion | Spain | 350 mg | concentrado para solución para perfusión | Marketed | Janssen-Cilag International N.V |
| Rybrevant | Canada | 350 MG / 7 ML | Solution | Marketed | Janssen INC |
| Rybrevant 1600 mg, oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant 2240 mg, oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant 2.400 mg oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant 3.520 mg oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant SC | Canada | 2240 MG / 14 ML | Solution | Marketed | Janssen INC |
| Rybrevant SC | Canada | 3520 MG / 22 ML | Solution | Marketed | Janssen INC |
| Rybrevant SC | Canada | 1600 MG / 10 ML | Solution | Marketed | Janssen INC |
| Rybrevant SC | Canada | 2400 MG / 15 ML | Solution | Marketed | Janssen INC |
| Rybrevant 350 mg, concentraat voor oplossing voor infusie | Netherlands | Concentraat voor oplossing voor infusie | Authorised | Janssen-Cilag International NV | |
| Rybrevant | Brazil | Authorised | Janssen-Cilag Farmacêutica Ltda | ||
| Rybrevant® | Serbia | 350mg/7mL | koncentrat za rastvor za infuziju | Authorised | PredstavniŠTvo Janssen-Cilag KFT Beograd |
| Rybrevant | Croatia | Marketed | |||
| Rybrevant Solution for Injection 160 mg/mL | Taiwan | 注射液劑 | Authorised | 嬌生股份有限公司 | |
| Rybrevant Concentrate for Solution for Infusion 50mg/ml | Taiwan | 注射劑 | Authorised | 嬌生股份有限公司 |
The same brand on several registers.
The companies holding its medicines, the most first.
Substances it shares a medicine with.
How the registers write it, in their own languages.
Compiled by Prognia from the public medicine registers of AEMPS, AIFA, ALIMS, Anvisa, CBG-MEB, EMA, FDA, HALMED, Health Canada, HSA and TFDA. Each medicine’s page names its own source, licence and attribution.
Report an error or request removalCorrections from a register or a company are welcome.
For reference and learning, not treatment advice. Always check the official product information.
